Biphenyl

Biphenyl

SCHEMBL2838222

COc1c(F)c(F)cc(C(=O)O)c1F.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.47
AKR1C1 Q04828 1/20 0.47
DHODH Q02127 1/20 0.43
ABCB1 P08183 1/20 0.43
ACLY P53396 6/20 0.42
FABP4 P15090 1/20 0.42
FABP5 Q01469 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
HNF4A P41235 2/20 0.40
ACMSD Q8TDX5 2/20 0.40
DHFR P00374 1/20 0.40
MCL1 Q07820 1/20 0.40
CYP2C9 P11712 1/20 0.40
IKBKB O14920 1/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607945 0.90 HSD17B10 (0.44) KDM4EALDH1A1HPGDNR1H2NR1H3
SCHEMBL27927680 0.89 HSD17B10 (0.43) KDM4EALDH1A1HPGDNR1H2NR1H3
Ethylene Glycol SCHEMBL2829965 0.84 HSD17B10 (0.40) NR1H2NR1H3CYP2C9MEN1KMT2A
Methylene Chloride SCHEMBL28420789 0.84 HSD17B10 (0.40) KDM4EALDH1A1NR1H2NR1H3CYP2C9
Biphenyl SCHEMBL2835047 0.84 GAA (0.44) AKR1C2AKR1C1DHODHACLYFABP4
SCHEMBL12315391 0.83 MAPT (0.47) ABCB1ACLYALDH1A1HPGDMEN1
SCHEMBL2831144 0.83 HSD17B10 (0.39) KDM4ENR1H2NR1H3CYP2C9TSHR
SCHEMBL28937180 0.83 HSD17B1 (0.47) MEN1KMT2A
SCHEMBL28937179 0.83 HSD17B10 (0.39) NR1H2NR1H3CYP2C9TSHRMEN1
1,3-Propanediol SCHEMBL2834709 0.81 HSD17B10 (0.38) NR1H2NR1H3CYP2C9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 AKR1C2 1435/4885AKR1C1 1866/4885DHODH 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.